A pill that makes pancreatic cancer disappear? What the daraxonrasib trial found

Wait 5 sec.

A report by The Guardian highlights promising trial results for daraxonrasib, an experimental pill for advanced pancreatic cancer. In a trial involving 61 patients whose cancer had spread to other organs, the drug stopped tumour growth in 90 per cent of participants, while tumours shrank or disappeared in over 60 per cent.In nearly 8 per cent of patients, tumours became undetectable on CT scans. About 76.6 per cent of participants were alive a year after starting treatment, compared with the usual 40-45 per cent survival rate among patients receiving chemotherapy alone.Although researchers have cautioned that the drug cannot yet be considered a cure and longer studies are needed, oncologists have described the findings as a significant breakthrough that could offer patients more time and potentially open avenues for treating other cancers driven by KRAS mutations.But what makes this treatment different from conventional chemotherapy? Speaking with indianexpress.com, Dr Parveen Jain, Senior Consultant and HOD–Medical Oncology, Aakash Healthcare, explains how the drug works and what these early findings mean for patients.DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.How does daraxonrasib work against pancreatic cancer?Most pancreatic cancers carry alterations in the KRAS gene, which send continuous signals that encourage cancer cells to grow and survive. Daraxonrasib is designed to block these faulty signals and disrupt the molecular pathways that sustain tumour growth.“Daraxonrasib is important because it targets the mechanism that sustains the tumour itself rather than the fast-dividing cells around it that some chemotherapies do,” says Dr Jain.Story continues below this adHe explains that conventional chemotherapy attacks rapidly dividing cells, including some healthy cells, whereas targeted therapies aim to block specific molecular pathways responsible for cancer growth.“What’s exciting is the specificity—we can target specific mutations that are the engines driving the cancer,” he adds.However, targeted treatment also comes with questions around potential side effects and the possibility of cancer cells developing resistance. Does an undetectable tumour mean the patient is cured? (Photo: Magnific)How significant are the trial results?The findings are particularly ‘encouraging’ because metastatic pancreatic cancer, which has spread to organs such as the liver and lungs, is difficult to treat.Story continues below this adDr Jain points out that approximately 90.2 per cent of patients in the trial achieved disease control, meaning their cancer either shrank or stopped growing. Just over 60.7 per cent experienced measurable tumour shrinkage, while 8.2 per cent had complete radiological responses, with no visible cancer on scans.“Controlling disease progression is an important treatment goal in patients with cancer that has spread to the liver, lungs or other organs,” he says.Does an undetectable tumour mean the patient is cured?“If a CT scan does not show a tumour, it is a good sign, but this does not mean that a patient is cured of cancer. Radiological methods can detect gross tumours but cannot detect individual or clumps of cancer cells that may be left behind,” says Dr Jain.These remaining cells could eventually multiply and cause the cancer to return. This is particularly concerning in pancreatic cancer, which can spread to other organs relatively early.Story continues below this ad“Thus, they could be considered as potential markers of deep tumour regression rather than cure,” he says.Long-term follow-up will be necessary to establish whether these responses are sustained and whether the treatment can eventually lead to durable remission.ALSO READ | What we know about India’s new ‘smart’ cancer drug that ‘could replace chemotherapy’Can daraxonrasib become a standard treatment?The reported one-year survival rate of 76.6 per cent is encouraging compared with historical survival figures for patients receiving chemotherapy alone. However, Dr Jain cautions against interpreting this as definitive evidence that the drug improves survival.“This is a small study of just 61 patients and uses a historical comparison to chemotherapy (rather than comparing two randomised groups),” he explains. He adds that subsequent trials are also examining daraxonrasib in combination with chemotherapy drugs such as gemcitabine and nab-paclitaxel.Story continues below this adLarger randomised phase III trials will be needed to establish whether the treatment improves overall survival or progression-free survival compared with standard chemotherapy. Long-term safety, treatment resistance, quality of life and the patient groups most likely to benefit will also need to be assessed.“The findings provide a new hope, but more evidence will be needed before we can make a definitive judgement on its use in routine cancer treatment,” he adds.DISCLAIMER: This article is based on information from the public domain and/or the experts we spoke to. Always consult your health practitioner before starting any routine.